---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-067483"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2024-06-03T23:59:59+00:00"
generated_at: "2026-06-01T06:55:43.134674+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics reports positive Phase 2a data for obesity drug GSBR-1290

## Summary
- GSBR-1290 achieved placebo-adjusted mean weight loss of 6.2% (p<0.0001) in Phase 2a obesity study at 12 weeks.
- Capsule to tablet PK study showed up to 6.9% placebo-adjusted weight loss (p<0.0001) with new tablet formulation.
- 67% of GSBR-1290 treated participants achieved ≥6% weight loss and 33% ≥10% loss vs 0% for placebo.
- Adverse events were GI-related; discontinuations 5% in Phase 2a and 11% in PK study; no liver injury.
- Phase 2b obesity study expected to begin Q4 2024 with ~300 participants using tablet formulation.

## SEC filing metadata
- accession: 0001104659-24-067483
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2024-06-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/0001104659-24-067483-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465924067483/tm2414821d7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-067483
- JSON: https://secwatch.observer/filing/0001104659-24-067483.json
- Plain text: https://secwatch.observer/filing/0001104659-24-067483.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.